
Oregon Housing and Community Services

Neeti Vyas, M.B.B.S., MPH, CIC
Congregate Care Epidemiologist
Population Support Team- Houseless
Infection Prevention and Control-Non-LTCF congregate settings




COVID-19 RESPONSE and RECOVERY UNIT
(CRRU)

New Cases	7 Day Daily Average of Cases	Cases Per 100k in Previous 7 Days	COVID-19 Patients Hospitalized†	Tests Reported	Test Positivity	New Deaths
1,564 ▼*	1,435	365.4	730 ▼	22,006	8.0%	33

* Arrows indicate an increase or decrease from the previous day. †Hospitalization data from Oregon's Hospital Capacity Web System (HOSCAP).

Daily Cases and 7 Day Moving Average over the Previous Six Weeks



<https://public.tableau.com/app/profile/oregon.health.authority.covid.19/viz/OregonCOVID-19Update/DailyDataUpdate>




Variants of Concern

Variants of Interest

Variants Being Monitored

Delta (B.1.617.2, AY sublineages) 6,817	There are no Variants of Interest at this time.	Alpha (B.1.1.7, Q Sublineages) 3,085 Beta (B.1.351 and sublineages) 233 Gamma (P.1 and sublineages) 1,181 Epsilon (B.1.427/B.1.429) 1,239 Eta (B.1.525) 9	Iota (B.1.526) 424 Kappa (B.1.617.1) 0 B.1.617.3 0 Mu (B.1.621) 50 Zeta (P.2) 8
--	---	---	---

Variant Prevalence Past Six Weeks



Outbreak Response

- Symptomatic/ positive individual identified- Inform local public health authority (LPHA) within 24 hours
- Connect with LPHA to establish a testing plan
- Facility-wide testing recommended- At least 2 rounds of negative testing recommended before outbreak is considered over
- Follow screening, masking, physical distancing, disinfection, ventilation etc. other mitigation measures

Guidance regarding at-home test kits

- These tests are considered less reliable than molecular and antigen tests conducted in diagnostic laboratories
- Patients with positive test results should be encouraged to seek confirmatory testing with a laboratory-based FDA EUA approved NAAT or antigen test for COVID-19.
- At-home COVID-19 test kits performed by prescription (e.g., Lucira) or as a point-of-care test under a CLIA waiver should be treated as a laboratory-based test
- These would have the same reporting requirements as any other laboratory-based test

Vaccine mandate for Healthcare workers

- ❖ On or before October 18, 2021, healthcare providers and healthcare staff must provide their employer, contractor or responsible party with either:
 - (a) Proof of vaccination showing they are fully vaccinated; or
 - (b) Documentation of a medical or religious exception.

- ❖ Vaccine mandate FAQ:
<https://sharedsystems.dhsoha.state.or.us/DHSForms/Served/le3879.pdf>

Third Dose vs. Booster Dose

- On Aug. 12, the U.S. Food and Drug Administration (FDA) adjusted the existing Emergency Use Authorizations (EUA) for the Pfizer and Moderna COVID-19 vaccines to allow immunocompromised people to receive a **third dose** of either vaccine.
- <https://sharedsystems.dhsoha.state.or.us/DHSForms/Served/le3819.pdf>
- As with other vaccines, a **booster shot** will strengthen the body's ability to prevent disease from the virus that causes COVID-19.
- <https://sharedsystems.dhsoha.state.or.us/DHSForms/Served/le3898B.pdf>

Third Dose vs. Booster Dose- Timeline

- A **third dose** of the Pfizer vaccine may be administered at least 28 days following the second dose of a two-dose regimen to immunocompromised people ages 12 and older.
- A **third dose** of the Moderna vaccine may be administered at least 28 days following the second dose of a two-dose regimen to immunocompromised people ages 18 and older.
- Based on scientific evidence, **booster doses** of the Pfizer vaccine are now available for some groups of people at least six months after their second dose

Third Dose- Eligibility

Imunocompromised individuals include people who:

- Are undergoing active treatment for solid tumor and hematologic malignancies
- Have received solid-organ transplant and are taking immunosuppressive therapy
- Have received CAR (chimeric antigen receptor)-T-cell or hematopoietic stem cell transplant (within two years of transplantation or are taking immunosuppression therapy)

Third Dose- Eligibility

- Have advanced or untreated HIV infection
- Have moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Are undergoing active treatment with high-dose corticosteroids (i.e., ≥ 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory

Booster Dose- Eligibility

- 65 years and older
- 18+ who have underlying medical conditions (Oregon considers all intellectual and developmental disabilities underlying medical conditions.)
- 18+ who work in high-risk settings
- 18+ who live in high-risk settings
- Booster doses are widely available through pharmacies, doctor's offices and clinics, as COVID-19 vaccine is today. Use the vaccine locator map to find a vaccine provider near you or call 211 or (866) 698-6155 for information and assistance in any language.